A case of tumor Necrosis factor- α inhibitors-induced pustular psoriasis

Annals of Dermatology

Volumn 22, Issue 2, 2010, Pages 212-215

  Park, Jae Jeong ^a   Lee, Seung Chul ^a  

^a Chonnam National University   (South Korea)

Author keywords

Adalimumab; Etanercept; Inhibitors; Pustular psoriasis; Tnf

Indexed keywords

EID: 77954711629     PISSN: 10139087     EISSN: None     Source Type: Journal    
DOI: 10.5021/ad.2010.22.2.212     Document Type: Article

References (16)

1. de Cannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-alpha in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-231. (Pubitemid 46294587)
2. Dika E, Varotti C, Bardazzi F, Maibach HI. Drug-induced psoriasis: an evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutan Ocul Toxicol 2006;25:1-11. (Pubitemid 43879257)
3. Choi YJ, Kim DS, Park JM, Oh SH, Park YK, Lee JH. A case of psoriasiform eruption triggered by tumor necrosis factoralpha antagonist therapy. Korean J Dermatol 2008;46:721-723.
4. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-279.
5. Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol 2007;8:143-155. (Pubitemid 46998542)
6. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001.
7. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202:135-143. (Pubitemid 41002916)
8. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-2179.
9. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359: 1187-1193. (Pubitemid 34304258)
10. Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol 2003;49:S105-111.
11. Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 2006;45:1121-1124. (Pubitemid 44542100)
12. Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 2007;66:419-421. (Pubitemid 46579648)
13. Lee JG, Park HJ, Lee YA, Hong SJ, Lee SH, Yang HI. Clinical improvement of ankylosing spondylitis on switching tumor necrosis factor inhibitors: a case report. Korean J Med 2008;75:S930-934.
14. Laas K, Peltomaa R, Kautiainen H, Leirisalo-Repo M. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol 2008;27:927-932.
15. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007;46:1191-1199. (Pubitemid 47053782)
16. Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007;66:1393-1397. (Pubitemid 47492489)